- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT01794663
Placebo-Controlled Study to Evaluate the Safety and Efficacy of OPN-305 in Preventing Delayed Renal Graft Function
A Three-Part, Multi-Centre, Randomised, Double-Blind, Placebo-Controlled, Parallel-Group, Sequential Adaptive, Phase II Study to Evaluate the Safety, Tolerability and Efficacy of OPN-305, a Humanised Monoclonal Antibody That Blocks Toll-Like Receptor 2, in Renal Transplant Patients at High Risk of Delayed Graft Function
When a patient receives a kidney transplant particularly if the kidney is from an older donor or one who has had the kidney removed after their heart has stopped, there is a risk that the newly transplanted kidney may not function immediately. If the delay in function means that dialysis is needed in the first 7 days after the transplantation then this is known as delayed graft function or dDGF. Also delayed graft function that does not require dialysis but is present because the serum creatinine does not fall sufficiently is known as functional delayed graft function or fDGF. This problem is often due to an excessive inflammatory reaction to not having had a blood supply between the time of donation and transplant.
OPN-305 is a monoclonal antibody that blocks Toll-like Receptor 2 which is thought to be partly responsible for increasing the risk of this inflammation. It is hoped that the effects of the inflammation will be reduced and therefore prevent dDGF and fDGF from occurring.
The purpose of the study is to explore how effective OPN-305 is in preventing dDGF and fDGF as well as improving other measures of kidney function and the overall safety of the antibody. In the first part of the study, each patient received an Infusion of one of three possible doses of OPN-305 or a placebo and in the second part the most suitable dose of OPN-305 and a placebo would be used. The purpose of this second part of the study is to find out if a dose of OPN-305 which has already been tested in an earlier part of this study can prevent kidney graft dysfunction. For the purposes of this study, kidney function will be assessed using the composite of delayed graft function (dDGF) because dialysis is necessary in the first 7 days and functional delayed graft function that does not require dialysis but is present because the serum creatinine, a key measure of renal function, does not fall sufficiently (fDGF) in the first 7 days post-transplant.
Protocol OPN305-103 follows out to 12 months post-transplant the clinical status and graft function of patients who have completed the 6-month post-transplant period under Part A or Part B of OPN305-102.
Study Overview
Status
Conditions
Intervention / Treatment
Study Type
Enrollment (Actual)
Phase
- Phase 2
Contacts and Locations
Study Locations
-
-
-
Linz, Austria, A-4020
- Research Site
-
-
-
-
-
Brussels, Belgium, 1090
- Research Site
-
Gent, Belgium, 9000
- Research Site
-
Leuven, Belgium, 3000
- Research Site
-
Liege, Belgium, 4000
- Research Site
-
-
-
-
-
Praha, Czech Republic, 14021
- Research Site
-
-
-
-
-
Bordeaux, France, 33076
- Research Site
-
Paris, France, 75743
- Research Site
-
Toulouse, France, 31409
- Research Site
-
-
-
-
-
Berlin, Germany, 10117
- Research Site
-
Berlin, Germany, 13353
- Research Site
-
Bochum, Germany, 44892
- Research Site
-
Bonn, Germany, 53127
- Research Site
-
Erlangen, Germany, 90154
- Research Site
-
Heidelberg, Germany, 69120
- Research Site
-
Koln, Germany, 51109
- Research Site
-
Mannheim, Germany, 68135
- Research Site
-
Munster, Germany, 48149
- Research Site
-
Tubingen, Germany, 72076
- Research Site
-
-
-
-
-
Groningen, Netherlands, 9700
- Research Site
-
Leiden, Netherlands, NL-2300 RC
- Research Site
-
Nijmegen, Netherlands, 6525
- Research Site
-
Rotterdam, Netherlands, 3015
- Research Site
-
-
-
-
-
Bydgoszcz, Poland, 85-094
- Research Site
-
Lodz, Poland, 90-153
- Research Site
-
Szczecin, Poland, 70-111
- Research Site
-
Warsaw, Poland, 02507
- Research Site
-
Warszawa, Poland, 02-006
- Research Site
-
-
-
-
-
Barcelona, Spain, 08036
- Research Site
-
Barcelona, Spain, 08003
- Research Site
-
Barcelona, Spain, 08907
- Research Site
-
Madrid, Spain, 28041
- Research Site
-
Santander, Spain, 39008
- Research Site
-
-
-
-
-
Zurich, Switzerland, 8091
- Research Site
-
-
-
-
-
London, United Kingdom, SE1 9RT
- Research Site
-
Newcastle upon Tyne, United Kingdom, NE7 7DN
- Research Site
-
-
-
-
California
-
Los Angeles, California, United States, 90033
- Research Site
-
-
District of Columbia
-
Washington, District of Columbia, United States, 20007
- Research Site
-
-
Florida
-
Tampa, Florida, United States, 33606
- Research Site
-
-
Illinois
-
Chicago, Illinois, United States, 60612
- Research Site
-
-
Louisiana
-
New Orleans, Louisiana, United States, 70112
- Research Site
-
New Orleans, Louisiana, United States, 70121
- Research Site
-
-
New Jersey
-
Livingston, New Jersey, United States, 07039
- Research Site
-
-
New York
-
Bronx, New York, United States, 10467
- Research Site
-
New York, New York, United States, 10065
- Research Site
-
-
Pennsylvania
-
Harrisburg, Pennsylvania, United States, 17105
- Research Site
-
-
South Carolina
-
Charleston, South Carolina, United States, 29425
- Research Site
-
-
Texas
-
Dallas, Texas, United States, 75246
- Research Site
-
Fort Worth, Texas, United States, 76104
- Research Site
-
-
Virginia
-
Richmond, Virginia, United States, 23298
- Research Site
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion criteria
INCLUSION CRITERIA FOR TRANSPLANT RECIPIENTS
First or second renal transplant recipient - for second renal transplantations;
- The second transplant should NOT be due to rejection
- Panel Reactive Antibody (PRA) should be <10%
- Minimum 3 months since the loss of the first transplanted kidney
Dialysis-dependent at the time of transplantation as documented by:
- Requirement for at least 2 dialysis sessions/week in the 56 days before transplantation
INCLUSION CRITERIA FOR DONOR KIDNEY:
- The donor kidney must be considered compatible according to local transplant guidelines
An ECD donor defined as:
o Extended Criteria Donor defined as:
- Donor ≥60 years of age
- Donor 50-59 years of age with two of three of the following criteria present:
- Death due to cerebrovascular accident
- Pre-existing history of systemic hypertension
- Terminal creatinine > 1.5mg/dL (132.6 µmol/L)
- Kidney allograft maintained in cold storage with or without machine perfusion
Exclusion Criteria
EXCLUSION CRITERIA FOR TRANSPLANT RECIPIENTS:
- Use of an investigational drug in the 30 days before Study Day 1
- Participation in any other research
- Known hypersensitivity to human monoclonal antibodies or any of the study-drug excipients
- Previous hypersensitivity to basiliximab or anti-thymocyte globulin (ATG)
- History or known HIV, HBV, or HCV-positive
- History of malignancy within the last five years, except excised squamous or basal cell carcinoma of the skin or cervical intraepithelial neoplasia
- Scheduled to undergo multi-organ transplantation
- Planned dual kidney transplantation
- Presence of clinically significant infections requiring continued therapy
- Active tuberculosis
- Existence of any surgical or medical condition, other than the current transplantation which, in the opinion of the investigator, might significantly alter the distribution, metabolism or excretion of study medication
- Presence of uncontrolled diabetes mellitus.
- Current drug and/or alcohol abuse
- History or presence of a medical condition or disease that in the investigator's assessment would place the patient at an unacceptable risk for study participation
- Lactating or pregnant woman
- Patient institutionalized by administrative or court order
EXCLUSION CRITERIA FOR ALL DONOR KIDNEYS
- DCD or SCD donor kidney
- Terminal creatinine >3mg/dL
- Donor who is known to have received an investigational drug for I-R injury or graft rejection (immunosuppressant) in the 48h before organ recovery
- Participation in any other research (drug or non-drug)
- Kidney donor <5 years of age or <20kg body weight
- Living donor allograft
- HLA or ABO incompatible kidney as defined by a negative cytotoxic crossmatch
- Donor institutionalized by administrative or court order
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Prevention
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: Double
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Placebo Comparator: Matching placebo
|
Intravenous infusion for 1 hour at start of transplant procedure
|
Experimental: OPN-305
|
Intravenous infusion for 1 hour at start of transplant procedure
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Measure of Early Graft Function EGF
Time Frame: First 7 days following renal transplantation
|
Initiation of dialysis in the first 7 days following renal transplantation and failure of serum creatinine to decrease by at least 10% daily on 3 successive days during the first week post transplantation
|
First 7 days following renal transplantation
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Creatinine at 7 and 14 days and at 1, 3 and 6 months
Time Frame: 7 and 14 days and at 1, 3 and 6 months
|
Measure of creatinine at 7 and 14 days and at 1, 3 and 6 months
|
7 and 14 days and at 1, 3 and 6 months
|
Cystatin C at 7 and 14 days and at 1, 3 and 6 months
Time Frame: 7 and 14 days and at 1, 3 and 6 months
|
Measure of Cystatin C at 7 and 14 days and at 1, 3 and 6 months
|
7 and 14 days and at 1, 3 and 6 months
|
Symmetrical dimethylarginine at 7 and 14 days and at 1, 3 and 6 months
Time Frame: 7 and 14 days and at 1, 3 and 6 months
|
Measure of symmetrical dimethylarginine at 7 and 14 days and at 1, 3 and 6 months
|
7 and 14 days and at 1, 3 and 6 months
|
Incidence of slow graft function
Time Frame: 5 days post-transplant
|
Slow graft function to be assessed over first 5 days post-transplant
|
5 days post-transplant
|
Serum creatinine over time
Time Frame: over the duration of follow-up
|
Measure of Serum creatinine over time
|
over the duration of follow-up
|
Composite endpoint
Time Frame: 6 months
|
Components of the composite endpoint are:
|
6 months
|
Time to biopsy-proven kidney allograft rejection
Time Frame: 6 months
|
Time to biopsy-proven kidney allograft rejection
|
6 months
|
Time to first dialysis or functional delayed graft function and delayed graft function duration
Time Frame: 30 days
|
Duration of DGF is defined as either: Time from transplantation to time of completion of final dialysis for DGF Time from transplantation to time when creatinine starts to fall by at least 10% without dialysis |
30 days
|
Blood and urine biomarkers for acute kidney injury (AKI)
Time Frame: days 2, 7, 14, 28, 90 and 180
|
Serum NGAL, urinary NGAL, α-GST, π-GST, KIM-1 and IL-18
|
days 2, 7, 14, 28, 90 and 180
|
Duration of initial hospitalization
Time Frame: 6 months
|
Duration of initial hospitalization
|
6 months
|
Duration of subsequent readmissions
Time Frame: 6 months
|
Duration of subsequent readmissions
|
6 months
|
Reason for subsequent readmissions
Time Frame: 6 months
|
Reason for subsequent readmissions
|
6 months
|
Number of Adverse events (AEs)
Time Frame: 6 months
|
Number of Adverse events (AEs)
|
6 months
|
Nature of Adverse events (AEs)
Time Frame: 6 months
|
Nature of Adverse events (AEs)
|
6 months
|
Incidence of infections
Time Frame: 6 months
|
Incidence of infections by category and organism
|
6 months
|
Rate of primary non-function (permanent lack of function of the allograft)
Time Frame: 6 months
|
6 months
|
|
Number of dialysis sessions between 0 and 30 days post-transplantation
Time Frame: 30 days
|
Number of dialysis sessions between 0 and 30 days post-transplantation
|
30 days
|
Collaborators and Investigators
Sponsor
Investigators
- Study Director: Robert M Miller, FRCS MBBS, OpsonaTherapeutics Ltd.
Study record dates
Study Major Dates
Study Start
Primary Completion (Actual)
Study Completion (Actual)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Estimate)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- OPN305-102
- 2012-001455-39 (EudraCT Number)
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Delayed Graft Function
-
Institute of Liver and Biliary Sciences, IndiaCompletedBiliary Complications | Graft Function, Delayed
-
Schroppel, Bernd, M.D.Alexion PharmaceuticalsTerminatedDelayed Function of Renal TransplantUnited States
-
Prolong PharmaceuticalsCompletedDelayed Function of Renal TransplantUnited States
-
Prolong PharmaceuticalsWithdrawnDelayed Function of Renal Transplant
-
MARIO ABBUD FILHOUnknownDelayed Function of Renal TransplantBrazil
-
Ohio State UniversityBristol-Myers SquibbTerminatedDelayed Graft FunctionUnited States
-
McGill University Health Centre/Research Institute...Astellas Pharma Canada, Inc.Unknown
-
First Affiliated Hospital Xi'an Jiaotong UniversityUnknownDelayed Graft FunctionChina
-
King Chulalongkorn Memorial HospitalRecruitingKidney Transplant; Complications | Delayed Graft Function | Kidney FunctionThailand
-
Columbia UniversityCompletedImplant or Graft; RejectionUnited States
Clinical Trials on OPN-305
-
Opsona Therapeutics Ltd.M.D. Anderson Cancer Center; Montefiore Medical Center; New York Presbyterian... and other collaboratorsCompletedMyelodysplastic SyndromeUnited States
-
Opsona Therapeutics Ltd.M.D. Anderson Cancer Center; Montefiore Medical Center; New York Presbyterian... and other collaboratorsCompletedMyelodysplastic SyndromeUnited States
-
Neuramedy Co. Ltd.Quotient SciencesNot yet recruitingParkinson DiseaseUnited Kingdom
-
Optinose US Inc.Terminated
-
Assiut UniversityUnknownDiabetic Nephropathies | Vascular CalcificationEgypt
-
Optinose US Inc.RecruitingBilateral Nasal PolyposisUnited States
-
Optinose US Inc.CompletedChronic RhinosinusitisUnited States, United Kingdom, Bulgaria, Canada, Georgia, Poland, Russian Federation, Sweden
-
KCRISIS Medical AGCompletedCoronary Artery Disease | Angina, Stable | Angina, UnstableSwitzerland
-
Optinose US Inc.CompletedChronic RhinosinusitisUnited States, Australia, Poland, New Zealand, Spain, Georgia, United Kingdom, Bulgaria, Czechia, Romania
-
Enanta Pharmaceuticals, IncICON Clinical Research; Triangle BiostatisticsCompletedNon-Alcoholic SteatohepatitisUnited States, United Kingdom, New Zealand, Canada, France, Puerto Rico